Equity Overview
Price & Market Data
Price: $1.38
Daily Change: -$0.09 / 6.52%
Range: $1.36 - $1.50
Market Cap: $84,713,096
Volume: 552,572
Performance Metrics
1 Week: -15.34%
1 Month: 1.47%
3 Months: -10.39%
6 Months: -90.50%
1 Year: -87.78%
YTD: -89.52%
Company Details
Employees: 171
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.